Remember the head-turning $7.4 billion merger between INC Research and inVentiv Health last May? Scrap those names, because the company just unveiled their new name today: Syneos Health.
In their former lives, INC was a clinical-focused organization headquartered in Raleigh, NC while Boston-based inVentiv specialized on the commercialization side. According to the CRO, their new brand embodies the “synchronizing” of those capabilities as well as a “new approach to problem-solving.”
Syneos’ (pronounced SIN-ee-ohs) rebranding follows that of IQVIA, the leader in the field. It now joins the ranks of integrated CROs that promise not only to be stewards of clinical tasks but active consultants in the entire process of bringing therapies to market.
“Syneos Health fully expresses our value proposition — that is, our ability to deliver integrated end-to-end solutions and create new paths for our customers to develop and commercialize their therapies,” said Alistair Macdonald, the former INC CEO now at the helm of Syneos.
Nasdaq will see Syneos under $SYNH starting January 9. Until then, it remains listed under $INCR, the ticker for INC Research, whose shareholders own 53% of the combined company per the merger agreement. The company’s shares have fallen 5% since the market opened.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 24,000+ biopharma pros who read Endpoints News by email every day.Free Subscription